The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Ketamine: Teaching an Old Drug New Tricks
Abstract
Ketamine has a special position among anesthetic drugs. It was introduced into clinical practice >30 yr ago with the hope that it would function as a "monoanesthetic" drug: inducing analgesia, amnesia, loss of consciousness, and immobility. This dream was not fulfilled because significant side effects were soon reported. With the introduction of other IV anesthetic drugs, ketamine's role diminished rapidly. However, it is still used clinically for indications such as induction of anesthesia in patients in hemodynamic shock; induction of anesthesia in patients with active asthmatic disease; IM sedation of uncooperative patients, particularly children; supplementation of incomplete regional or local anesthesia; sedation in the intensive care setting; and short, painful procedures, such as dressing changes in burn patients. However, recent insights into ketamine's anesthetic mechanism of action and its neuronal effects, as well as a reevaluation of its profound analgesic properties, offer the potential of expanding this range of indications. In addition, studies with the S(+) ketamine isomer suggest that its use may be associated with fewer side effects than the racemic mixture. In this article, we review the mechanism of action of ketamine anesthesia, the pharmacologic properties of its stereoisomers, and the potential uses of ketamine for preemptive analgesia and neuroprotection. Several aspects discussed herein have been reviewed previously [1-4]. Clinical Pharmacology Commercial ketamine is a racemic mixture consisting of two optical enantiomers, R(-) and S(+) (Figure 1), and the preservative benzethonium chloride. Pharmacokinetically, ketamine has relatively short distribution and elimination half-lives: the alpha-elimination phase lasts only a few minutes, and the beta-elimination half life is 2-3 h. The compound is metabolized extensively by the hepatic cytochrome p450 system; its primary metabolite norketamine is only one-third to one-fifth as potent as the original compound but may be involved in the prolonged analgesic actions of ketamine. The metabolites of norketamine are excreted by the kidneys.Figure 1: Structural formulas of the two enantiomers of ketamine.Classic ketamine anesthetic effects are best described as a dose-dependent central nervous system (CNS) depression that leads to a so-called dissociative state, characterized by profound analgesia and amnesia but not necessarily loss of consciousness. Although not asleep, the subject seems completely unaware of the environment. Suggested mechanisms for this form of catalepsy include electrophysiologic inhibition of thalamocortical pathways and stimulation of the limbic system. Ketamine has other effects besides analgesia and amnesia. Effects on the respiratory system are generally beneficial: it is a well documented bronchodilator [5], it causes minimal respiratory depression with only mild hypercapnia [6] in clinically relevant doses, and protective airway reflexes are more likely to be preserved than with other IV anesthetics. However, increased oral secretions can occur. Ketamine often produces significant increases in blood pressure and heart rate [7], and increases in pulmonary artery pressure have been reported, especially in patients with preexisting heart disease [8,9]. These effects are due to sympathetic stimulation; ketamine's direct effect on the heart is depressant, S(+) less than R(-) [10]. Recovery time is dose-dependent, and emergence is, at times, complicated by psychotomimetic reactions (hallucinations, vivid dreams), which can be highly unpleasant. The manufacturer lists the presence of uncontrolled arterial hypertension or hypersensitivity to the drug as contraindications to the use of ketamine. However, caution has also been suggested when the drug is used in patients with coronary artery disease [11] or right heart failure [12]. Mechanisms of Action Ketamine's neuropharmacology is complex. The compound interacts with multiple binding sites, including N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptors, nicotinic and muscarinic cholinergic, and monoaminergic and opioid receptors. In addition, interactions with voltage-dependent ion channels such as Na and L-type Ca channels have been described. Inhibition of neuronal Na channels provides a modest local anesthetic effect of the compound, whereas Ca channel blockade may be responsible for cerebral vasodilation [13]. All of these interactions may play a role in ketamine's pharmacological and clinical properties. However, NMDA receptor antagonism accounts for most of the analgesic, amnestic, psychotomimetic, and neuroprotective effects of the compound. NMDA Glutamate Receptors The NMDA receptor is an ionotropic receptor (ligandgated ion channel) that is activated by glutamate, the most abundant excitatory neurotransmitter in the CNS (Figure 2). The channel is permeable to Ca and, to a lesser degree, to Na and K. It requires glycine as an obligatory co-agonist and is i
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate, nitric oxide and cell-cell signalling in the nervous system
Garthwaite, J. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90022-m · Cited by 2,402
Woolf, C. J., & Thompson, S. W. N. (1991) · Pain · doi:10.1016/0304-3959(91)90100-c · Cited by 1,963
Ketamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,237
NMDA Antagonist Neurotoxicity: Mechanism and Prevention
Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991) · Science · doi:10.1126/science.1835799 · Cited by 841
The prevention of postoperative pain
Wall, P. D. (1988) · Pain · doi:10.1016/0304-3959(88)90286-2 · Cited by 731
Ketamine: an update on the first twenty-five years of clinical experience
Reich, D. L., & Silvay, G. (1989) · Canadian Journal of Anaesthesia · doi:10.1007/bf03011442 · Cited by 708
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
Oye, I., Paulsen, O., & Maurset, A. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11430-4 · Cited by 429
Pharmacology of Ketamine Isomers in Surgical Patients
White, P. F., Ham, J., Way, W. L., & Trevor, A. (1980) · Anesthesiology · doi:10.1097/00000542-198003000-00008 · Cited by 425
COMPARATIVE PHARMACOLOGY OF THE KETAMINE ISOMERS
WHITE, P. F., SCHÜTTLER, J., SHAFER, A., STANSKI, D. R., HORAI, Y., & TREVOR, A. J. (1985) · British Journal of Anaesthesia · doi:10.1093/bja/57.2.197 · Cited by 415
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Ketamine-Induced Neuronal Cell Death in the Perinatal Rhesus Monkey
Slikker, W., Zou, X., Hotchkiss, C. E., Divine, R. L., Sadovova, N., Twaddle, N. C., Doerge, D. R., Scallet, A. C., Patterson, T. A., Hanig, J. P., et al. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm084 · Cited by 608
Metadata
- Authors
- Kohrs, R., & Durieux, M. E.
- Venue
- Anesthesia & Analgesia
- Published
- 1998-11
- Volume
- 87
- Issue
- 5
- Pages
- 1186-1193
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W2083947597
- Cited by
- 604
- References
- 69
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine: Teaching an Old Drug New Tricks. https://app.cochat.ai/papers/10.1097/00000539-199811000-00039
- The paper
- Kohrs, R., & Durieux, M. E. (1998). Ketamine: Teaching an Old Drug New Tricks. Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199811000-00039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.